<DOC>
	<DOCNO>NCT00496587</DOCNO>
	<brief_summary>The goal clinical research study learn combination 3 drug ( gemcitabine , capecitabine , bevacizumab ) help control metastatic unresectable renal cell carcinoma . The safety drug combination also test .</brief_summary>
	<brief_title>Capecitabine , Gemcitabine , Bevacizumab Combination Patients With Sarcomatoid Renal Cell Carcinoma</brief_title>
	<detailed_description>Gemcitabine capecitabine design disrupt growth cancer cell , may cause cancer cell start die . Bevacizumab drug bind inhibits Vascular Endothelial Growth Factor ( VEGF ) , blood-vessel stimulating agent unusually high level kidney cancer . If find eligible take part study , receive gemcitabine , capecitabine , bevacizumab 28 day cycle . Capecitabine take mouth ( food ) , twice daily , Days 1-21 . Gemcitabine give needle vein arm 30 minute Days 1 15 . Bevacizumab give needle vein arm Days 1 15 . It give 120 minute Cycle 1 60 minute cycle . Your doctor may decide give bevacizumab 30 minute tolerate treatment well . On first day cycle , blood ( 2 teaspoon ) urine collect treatment routine test . You also blood draw Day 15 ( 2 teaspoon ) routine test . Every 8 week , CT scan chest , abdomen , pelvis chest x-ray . You ask drug currently take complete physical exam . You ask side effect might experience since last visit ability perform daily activity evaluate . Repeat bone scan MRI brain may do doctor think necessary . You continue receive treatment maximum 12 month . However , benefit treatment , may able continue receive study . You take study disease get bad , side effect intolerable , develop another illness prevent receive treatment . This investigational study . Gemcitabine , capecitabine , bevacizumab FDA approve commercially available . Up 40 participant may take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Histologically demonstrate , metastatic unresectable sarcomatoid carcinoma kidney , define follow : • A tumor biopsy ( primary metastasis ) must show least one focus RCC ( one recognize type ) ; , • A tumor biopsy ( primary metastasis ) must least 10 % sample showing sarcomatoid histology . 2 . ( # 1 cont 'd ) • Patients primary tumor place eligible percentage sarcomatoid dedifferentiation needle biopsy ( primary metastasis ) , radiographic appearance primary tumor CT scan typical RCC . For patient , due small tumor sample , require identify area typical RCC histology long morphologic immunostaining characteristic consistent RCC . 3 . At least one site measurable disease ( may include primary tumor ) . 4 . No prior cytotoxic chemotherapy . Any prior immunotherapy permit . 5 . No prior bevacizumab treatment . Prior sorafenib sunitinib permit . 6 . Zubrod performance status 2 well 7 . Adequate organ bone marrow function : • Absolute Neutrophil Count ( ANC ) &gt; /= 1,500 • Platelets &gt; /=100,000 • Total bilirubin &lt; /= 1.5 mg/dl • AST ALT &lt; /= 3x upper limit normal • Creatinine clearance &gt; 50 cc/min ( measure calculate Cockcroft formula : Creatinine Clearance = [ ( 140 age ) x wt ( kg ) ] / [ 72 x creat ( mg/dl ) ] , females x 0.85 . Patients creatinine clearance 3050 ml/min eligible initial dosereduction capecitabine ( 1 ) dose level . 8 . Female patient childbearing potential ( last menses &lt; 2 year ) must negative blood pregnancy test within 7 day prior start treatment . 9 . All patient must agree practice adequate contraception sexually active duration trial 2 month discontinuation study drug 10 . Written informed consent . 1 . Patients history myocardial infarction , transient ischemic attack ( TIA ) , stroke , pulmonary embolism , history deep vein thrombosis within precede 12 month . 2 . Patients major risk bleeding , active brain metastasis . Patients control small brain metastasis eligible base clinical assessment actual bleeding risk . 3 . Patients history major surgical procedure within precede 28 day . 4 . Patients baseline blood pressure &gt; /= 140 systolic &gt; /= 90 diastolic . 5 . Patients nephrotic syndrome ( proteinuria &gt; 2 gram per 24 hour ) 6 . History malignancy , unless clinically nonthreatening ( nonmelanoma skin cancer ) control 2 year prior study entry . 7 . Prior treatment gemcitabine , capecitabine , fluoropyrimidine . 8 . Prior unanticipated severe reaction fluoropyrimidine therapy know hypersensitivity 5FU . 9 . Any concurrent chemotherapy radiotherapy . 10 . Lack physical integrity upper gastrointestinal tract , inability swallow tablet malabsorption syndrome . 11 . Clinically significant cardiac disease well control medication , symptomatic coronary artery disease , congestive heart failure , cardiac arrhythmia . 12 . Serious concurrent infection serious medical condition , include uncontrolled diabetes . 13 . Any serious nonhealing wound , ulcer , active bone fracture . 14 . Any concurrent coumadin therapy . Patients previously coumadin maintenance may switch aspirin lowmolecularweight heparin . 15 . Patients organ allograft . 16 . Unwillingness give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Genitourinary</keyword>
	<keyword>Kidney Cancer</keyword>
	<keyword>Sarcomatoid Renal Cell Carcinoma</keyword>
	<keyword>Renal Cell Carcinoma</keyword>
	<keyword>RCC</keyword>
	<keyword>Sarcomatoid Carcinoma Kidney</keyword>
	<keyword>Unresectable renal cell carcinoma</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Xeloda</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Gemzar</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Anti-VEGF monoclonal antibody</keyword>
	<keyword>rhuMAb-VEGF</keyword>
	<keyword>Avastin</keyword>
	<keyword>Vascular Endothelial Growth Factor</keyword>
	<keyword>VEGF</keyword>
</DOC>